

NCT02749617 Raw comparison:

Summary:
CHIA has 17 criteria while your personal folder has 18 criteria
Total found criteria: 17/17
Total not Found: 0/17
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patients with diagnosis of multiple myeloma        │ Patients with diagnosis of multiple myeloma        │
│ according to criteria of the International Myeloma │ according to criteria of the International Myeloma │
│ Working Group                                      │ Working Group                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients in whom a LEN-DEX-based treatment regimen │ Patients in whom a LEN-DEX-based treatment regimen │
│ is indicated                                       │ is indicated                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adult patients ≥ 19 years of age who are able to   │ Adult patients ≥ 19 years of age who are able to   │
│ freely provide informed consent                    │ freely provide informed consent                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant antiplatelet or anticoagulant use      │ Concomitant antiplatelet or anticoagulant use      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Calculated creatinine clearance < 30 mL/min by     │ Calculated creatinine clearance \< 30 mL/min by    │
│ Cockcroft-Gault formula                            │ Cockcroft-Gault formula                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alanine aminotransferase (ALT) or aspartate        │ Alanine aminotransferase (ALT) or aspartate        │
│ aminotransferase (AST) > 3 times upper limit of    │ aminotransferase (AST) \> 3 times upper limit of   │
│ normal (ULN)                                       │ normal (ULN)                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total bilirubin > 2 x ULN                          │ Total bilirubin \> 2 x ULN                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Thrombocytopenia < 50 x 10 gigalitres (Gl)         │ Thrombocytopenia \< 50 x 10 gigalitres (Gl)        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ High bleeding risk or spontaneously prolonged      │ High bleeding risk or spontaneously prolonged      │
│ prothrombin time or activated partial              │ prothrombin time or activated partial              │
│ thromboplastin time > 1 5 x ULN                    │ thromboplastin time \> 1 5 x ULN                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body weight <50 or >120 kg                         │ Body weight \<50 or \>120 kg                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concomitant use of CYP3A4 or p-glycoprotein        │ Concomitant use of CYP3A4 or p-glycoprotein        │
│ inducers or inhibitors                             │ inducers or inhibitors                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of Ginkgo biloba or St John's Wort within 14   │ Use of Ginkgo biloba or St John's Wort within 14   │
│ days before first dose of study drug               │ days before first dose of study drug               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Dexamethasone use within last 3 months             │ Dexamethasone use within last 3 months             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of Childbearing potential without proper     │ Women of Childbearing potential without proper     │
│ contraceptive measures pregnancy or breast feeding │ contraceptive measures pregnancy or breast feeding │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy less than 3 months                 │ Life expectancy less than 3 months                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to swallow or issues with malabsorption  │ Inability to swallow or issues with malabsorption  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other medical social logistical geographical   │ Any other medical social logistical geographical   │
│ or psychological factors which in the opinion of   │ or psychological factors which in the opinion of   │
│ the investigator would prohibit follow-up          │ the investigator would prohibit follow-up          │
│ compliance and study completion                    │ compliance and study completion                    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 19 Years │
╘═══════════════════════════════════╛